Antihypertensive therapy increases natural immunity response in hypertensive patients

Publication date: Available online 26 October 2015 Source:Life Sciences Author(s): Henrique Andrade R. Fonseca, Francisco A. Fonseca, Lívia C. Lins, Andrea M. Monteiro, Henrique T. Bianco, Sergio A. Brandão, Rui M. Povoa, Luiz Juliano, Antônio M. Figueiredo-Neto, Paulo Boschcov, Magnus Gidlund, Maria C. Izar Aims The aim of this work was to evaluate the effects of treatment of hypertension on the autoantibodies to apolipoprotein B-derived peptides (anti-ApoB-D peptide Abs) response, inflammation markers and vascular function. Main methods Eighty-eight patients with hypertension (stage 1 or 2) were recruited and advised to receive perindopril (4mg), hydrochlorothiazide (25mg), or indapamide (1.5mg) for 12weeks in a blinded fashion. Office and 24-h ambulatory blood pressure monitoring (24h ABPM), flow-mediated dilatation (FMD), nitrate-induced dilatation (NID), titers of IgG and IgM anti-ApoB-D peptide Abs, hsCRP, and interleukins (IL-8 and IL-10) were evaluated at baseline and 12weeks after therapies. Key findings All treatments reduced office BP, and improved FMD (P <0.05 vs. baseline). The NID was improved only in the perindopril arm (P <0.05 vs. baseline). The 24h-ABPM was reduced with perindopril and hydrochlorothiazide therapies (P <0.05 vs. baseline), but not with indapamide, and this effect was followed by increase in titers of IgM Anti-ApoB-D peptide Abs (P <0.05 vs. baseline), without modifications in tite...
Source: Life Sciences - Category: Biology Source Type: research